<DOC>
	<DOCNO>NCT00733031</DOCNO>
	<brief_summary>The primary purpose study find maximum tolerate dose experimental drug call AZD6918 base side effect experience patient advanced solid malignancy receive daily AZD6918 alone . It possible AZD6918 administer twice daily . Then maximum tolerated dos combination either gemcitabine pemetrexed also investigate .</brief_summary>
	<brief_title>Phase I , Open-label , Dose-escalation , Safety PK Study AZD6918</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Advanced solid tumor standard treatment exist longer effective . For chemotherapy combination treatment , must suitable treatment either gemcitabine pemetrexed . Relatively good overall health cancer . Poor bone marrow function ( produce enough blood cell ) . Poor liver kidney function . Serious heart condition History uncontrolled epilepsy , Parkinson 's disease , Alzheimer 's disease , brain tumor uncontrolled psychiatric nervous system condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase I ,</keyword>
	<keyword>cancer ,</keyword>
	<keyword>solid tumor ,</keyword>
	<keyword>advanced solid malignancy ,</keyword>
	<keyword>dose escalation ,</keyword>
	<keyword>combination treatment ,</keyword>
	<keyword>TRK inhibitor</keyword>
</DOC>